InSilicoTrials Appoints Mark Lovern as Chief Platform Officer
Move marks commitment to leading the frontier of AI-driven innovation and simulation in life sciences, company says.
InSilicoTrials revealed that it has officially hired Mark Lovern to be its new chief platform officer. In his new role, Lovern will focus on combining his scientific knowledge with artificial intelligence (AI), machine learning (ML) and simulation technologies, along with an in-depth understanding of regulatory science, to drive the development of the InSilicoTrials.com platform and position it as a catalyst for hyper-accelerating life science R&D.
"Mark's extensive experience and mastery in model-informed drug development align seamlessly with our vision of revolutionizing the life sciences industry," said Luca Emili, CEO, InSilicoTrials, in a company press release. "His prior achievements, combined with our groundbreaking AI and simulations platform, will surely take our capabilities to unprecedented heights.”
Reference: Mark Lovern Joins InSilicoTrials as Chief Platform Officer. PR Newswire. October 17, 2023. Accessed October 19, 2023. https://www.prnewswire.com/news-releases/mark-lovern-joins-insilicotrials-as-chief-platform-officer-301958909.html
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
